VANCOUVER, March 08, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with University of Carleton University (“Carleton”) for TD-0148A’s…

Source

Previous articleIs 18-MC a Psychedelic Drug?
Next articleCybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021